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Background: Liver ﬁbrosis is a consequence of chronic liver injury and can further progress to hepatocellular
carcinoma (HCC). Fibrogenesis involves activation of hepatic stellate cells (HSC) and proliferation of hepa-
tocytes upon liver injury. HCC is frequently associated with overexpression of the proto-oncogene c-myc.
However, the impact of c-myc for initiating pathological precursor stages such as liver ﬁbrosis is poorly
characterized. In the present study we thus investigated the impact of c-myc for liver ﬁbrogenesis.
Methods: Expression of c-myc was measured in biopsies of patients with liver ﬁbrosis of different etiologies
by quantitative real-time PCR (qPCR). Primary HSCwere isolated frommice with transgenic overexpression
of c-myc in hepatocytes (alb-myctg) and wildtype (WT) controls and investigated for markers of cell cycle
progression and ﬁbrosis by qPCR and immunoﬂuorescence microscopy. Liver ﬁbrosis in WT and alb-myctg
mice was induced by repetitive CCl4 treatment.
Results: We detected strong up-regulation of hepatic c-myc in patients with advanced liver ﬁbrosis. In return,
overexpression of c-myc in alb-myctg mice resulted in increased liver collagen deposition and induction of
α-smooth-muscle-actin indicating HSC activation. Primary HSC derived from alb-myctg mice showed enhanced
proliferation and accelerated transdifferentiation into myoﬁbroblasts in vitro. Accordingly, ﬁbrosis initiation in
vivo after chronic CCl4 treatment was accelerated in alb-myctg mice compared to controls.
Conclusion: Overexpression of c-myc is a novel marker of liver ﬁbrosis in man and mice. We conclude that
chronic induction of c-myc especially in hepatocytes has the potential to prime resident HSC for activation,
proliferation and myoﬁbroblast differentiation.© 2013 Elsevier B.V. All rights reserved.1. Introduction
The transcription factor c-myc orchestrates the expression of more
than 15% of all human genes and thus mediates important biological
effects including cell growth, proliferation, loss of differentiation and
apoptosis [1–3]. One of the biological key functions of c-myc is its ability
to promote cell cycle progression. In quiescent cells, c-myc expression is
virtually undetectable. However, mitogenic stimulation of quiescent
cells elicits a rapid rise in c-myc expression resulting in induction
of G1-speciﬁc cyclin-dependent kinases including cyclin E–Cdk2
complexes and subsequent onset of DNA replication. Hence, ectopic
overexpression of c-myc in experimental settings is frequently sufﬁ-
cient to drive quiescent cells into the progressive phase of the cellCl4, carbon tetrachloride; HCC,
, non-parenchymal cells; PCNA,
ime polymerase chain reaction;
: +49 241 80 82455.
rights reserved.cycle [4–8]. C-myc is frequently deregulated or constitutively expressed
in many human cancers [4]. In the liver, transgenic overexpression of
c-myc inmurine hepatocytes is sufﬁcient to induce liver tumors although
with high latency [9,10]. The gene signature of these tumors is similar to a
group of slow-growing human hepatocellular carcinoma (HCC) [11].
HCC is one of the most common primary cancers and predominantly
develops as a consequence of chronic liver injury in a multi-step process
involving formation of liver ﬁbrosis and cirrhosis. Hepatic ﬁbrosis refers
to the accumulation of extracellularmatrix in response to acute or chronic
liver injury from a wide variety of etiologies. A complex interplay among
different hepatic cell types takes place during hepatic ﬁbrogenesis. Hepa-
tocytes are targets for most hepatotoxic agents, including hepatitis virus-
es, alcohol metabolites, and bile acids [12]. Damaged hepatocytes release
pro-ﬁbrotic signals and induce the recruitment of inﬂammatory cells,
which eventually leads to activation of hepatic stellate cells (HSC). In
response, resident quiescentHSC start to proliferate and transdifferentiate
into a myoﬁbroblast-like cell producing alpha-smooth-muscle-actin
(α-SMA) and further extracellular matrix proteins [13–16]. Thus, re-
generation of hepatocytes and activation of HSCs during chronic liver
injury involves transition of these normally quiescent cells into the
1766 Y.A. Nevzorova et al. / Biochimica et Biophysica Acta 1832 (2013) 1765–1775cell cycle leading to cell proliferation. We recently demonstrated that
the cell cycle mediator cyclin E1 is essential for proliferation and activa-
tion of HSC but less relevant for proliferation of regenerating hepato-
cytes [17,18]. However, the role of c-myc – which is thought to act
upstream of cyclin E1 – for initiation and progression of liver ﬁbrosis is
largely unknown.
Here, we investigated the contribution of c-myc for hepatic
ﬁbrogenesis. We show that c-myc is over-expressed in livers of
patients and mice with advanced liver ﬁbrosis and provide further
evidence that chronic c-myc expression especially in hepatocytes
predisposes to accelerated ﬁbrogenesis through crosstalk with HSC.2. Materials and methods
2.1. Human liver samples
Human liver samples were available from routine liver biopsies or
from explanted cirrhotic livers resulting from transplantation, as de-
scribed recently [19] and are further characterized in Supplementary
Table 1. Grading and staging of all liver specimens were performed
according to Desmet–Scheuer score by a pathologist who was blinded
for experimental data. Liver samples with signs of HCC were excluded
from further analysis. Control liver samples without ﬁbrosis were
obtained from unaffected areas of liver resections for secondary
liver malignancy (mostly metastasis of colorectal cancer). The study
protocol was approved by the ethics committee of University Hospital
Aachen, and conducted according to the principles expressed in the
Declaration of Helsinki. Human liver tissues were either subjected
to RNA isolation or parafﬁn embedded and stained with a c-myc anti-
body (Abcam, Cambridge, UK).2.2. Maintenance and treatment of mice
All animals were maintained in the animal facility of the University
Hospital Aachen in a temperature-controlled room with 12-hour light/
dark cycle. Animal husbandry and procedures were approved by the
authority for environment conservation and consumer protection of the
state North Rhine-Westfalia (LANUV, Germany). For our study we used
male transgenic mice carrying a c-myc transgene under the control of
the hepatocyte-speciﬁc albumin promoter (alb-myctg) as previously de-
scribed [20]. As controls, we used wildtype (WT) littermates derived
from heterozygous breeding couples.
Liver ﬁbrosis was induced in age-matched male mice at the age of
6 to 8 weeks (n = 5–10 per group). Mice were treated with carbon
tetrachloride (CCl4; Merck; 0.6 mL/kg of body weight i.p.) diluted in
corn oil or with corn oil only (controls). The animals received CCl4
twice aweek for 2 weeks andwere sacriﬁced 48 h after the last injection.2.3. Isolation of hepatic stellate cells (HSC) and primary hepatocytes
HSC were isolated from adult male mice in a C57BL/6 background
weighting approximately 25 g following the collagenase method
as described recently [17]. Freshly isolated HSC were washed and
plated in 6-well plates (Falcon) at a density of 150,000 cells per
well and cultivated in DMEM supplemented with 10% FCS 4 mmol/l L-
glutamine and4 mmol/l penicillin/streptomycin (PAA, Pasching, Austria).
Primary mouse hepatocytes were isolated from 7 to 8-week-old
mice by collagenase perfusion [21]. Live cells were plated on collagen
type 1 coated petri dishes at a density of 1.2 × 104/cm2 in DMEM
medium (PAA Laboratories GmbH, Pasching, Austria) supplemented
with L-glutamine, high glucose (4.5 g/l) and 100 U/ml penicillin/
streptomycin. Conditioned medium (CM) was collected from hepa-
tocytes grown in DMEM supplemented with 0.2% FCS for 24 h in
order to minimize interference with factors present in serum.2.4. Histological evaluation and immunoﬂuorescence stainings of liver
sections and isolated HSC
Immunoﬂuorescence staining of HSC on cover slips was performed
according to our recent report [17] using primary antibodies for α-SMA
(Sigma, Steinheim, Germany), Ki-67 (Dako, Glostrup, Denmark), c-myc
and cyclin E (Santa Cruz, CA). Allﬂuorescence-labeled cellswere analyzed
and documented using an Imager Z1 ﬂuorescence microscope together
with Axiovision software (Carl Zeiss, Jena, Germany).
Hepatic tissueswereﬁxed in 4%paraformaldehyde (PFA) immediately
after extraction, embedded in parafﬁn, sectioned and subjected to stain-
ing forH&E, Sirius red andKi-67 as described recently [17]. Immunostain-
ing of Platelet-derivedGrowth Factor B (PDGF-B)was performedusing an
Anti-PDGF BB antibody from Abcam (Cambridge, UK).
Quantitative determination of liver ﬁbrosis in mice was assessed
histologically byquantiﬁcationof Sirius red-positive areas as described re-
cently [22]. Brieﬂy, aminimum of 10 photographs of randomhigh-power
ﬁelds (100× magniﬁcations) were taken of each Sirius red-stained liver
section. Pictures containing large bile ducts or vessels were excluded
from further analysis. Images were converted to greyscale and subjected
to signal quantiﬁcation using free NIH ImageJ software (http://imagej.
nih.gov/ij/, National Institutes of Health, Bethesda, MD) according to the
provider's instructions.2.5. RNA isolation and quantitative real-time PCR analysis (qPCR)
The procedure to isolate total RNA and perform qPCR was performed
as described recently [17]. All measurements were normalized using
GAPDH expression as an internal standard and calculated as fold induc-
tion in comparison to untreated controls. The primer sequences are indi-
cated in Supplementary Table 2.2.6. Immunoblot analysis
Western blotswere carried out according to standard procedures [17].
Membranes (Whatman® Protran®) were probed with antibodies for
c-myc (Santa Cruz), α-SMA (Sigma, Steinheim, Germany), collagen 1
(PS065 Monosan, Beutelsbach, Germany) and PCNA (Invitrogen). As
secondary antibodies, anti-rabbit-HRP (Cell Signaling) and anti-mouse-
HRP (Santa Cruz) were used. GAPDH probing was performed as internal
control using an antibody from AbD seroTec (Kidlington, UK).2.7. Statistical analysis
Data are expressed as mean ± standard deviation of the mean.
Statistical signiﬁcance was determined by two-way analysis of vari-
ance followed by a Student's t test.3. Results
3.1. Liver ﬁbrosis in patients is associated with induction of c-myc
Wedetermined c-myc expression in liver biopsies frompatients with
liver ﬁbrosis of different etiologies (see Supplementary Table 1). Hepatic
c-myc mRNA expression was approximately tenfold up-regulated in pa-
tientswith advanced (F3) liver ﬁbrosis and also signiﬁcantly increased in
patients with liver cirrhosis (F4, Fig. 1A). In line with these ﬁndings,
immunohistological analysis of these samples (F3, F4) revealed a signiﬁ-
cant increase in c-myc expression especially in hepatocytes but also in
non-parenchymal liver cells (Fig. 1B). Thus, c-myc is deregulated in
the liver during ﬁbrogenesis, which might be important for disease
progression.
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Fig 1. Liver ﬁbrosis in patients is associated with induction of c-myc. Liver biopsies from healthy human livers (F0) and patients with advanced liver ﬁbrosis (F1, F3) or liver cirrhosis
(F4) were analyzed for (A) gene expression of c-myc via qPCR and (B) in situ c-myc protein expression (brown) via immunohistochemistry. *: p b 0.05; **: p b 0.01.
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The role of c-myc for the initiation and progression of liver ﬁbrosis
was further investigated using transgenic mice over-expressing c-myc
in hepatocytes (alb-myctg). Thesemice resemble a well-established an-
imal model of hepatocarcinogenesis characterized by low proliferation,
high apoptosis and development of slow-growing liver tumors with
long latency [23]. Accordingly, in 45-week-old alb-myctg mice less
than 40% of the animals developed spontaneous HCCs [9]. Hepatic
c-myc mRNA expression in these mice showed high variation ranging
from 40 to 200-fold expression over baseline. However c-myc protein
was detected in all investigated mice between 10 and 65 weeks of age
(Supplementary Fig. 1A–B).
We next tested spontaneous proliferation and apoptosis in the liver
of alb-myctg mice at different age. Of note, mature alb-myctg mice
revealed constitutive expression of the positive cell cycle mediator
Proliferating-Cell-Nuclear-Antigen (PCNA) and simultaneous activation
of the pro-apoptotic protein caspase-3 (Fig. 2A). Increased cell cycle
activity in hepatocytes and non-parenchymal cells of alb-myctg mice
was conﬁrmed by demonstrating elevated numbers of Ki-67 positive
cells (indicative of overall cell cycle activity), and by the up-regulation
of positive cell cycle mediators such as pRb, cyclin E1 and cyclin A2
(Supplementary Fig. 1C–E). Despite detectable caspase-3 activation in
alb-myctg mice, we observed a rather modest liver apoptosis in these
mice at all age cohorts investigated (Supplementary Fig. 2A). However,
liver transaminases in alb-myctg mice were only slightly but not signiﬁ-
cantly elevated in youngermice (until the age of 35 weeks), while older
mice showed a stronger induction of transaminase values presumably
due to the ﬁrst appearance of liver tumors (Supplementary Fig. 2B).
We therefore concluded that mild chronic liver injury (i.e. apoptosis)
in alb-c-myctg livers may trigger a constant compensatory proliferation
of surrounding hepatocytes.
Remarkably, liver tissue of alb-myctg mice exhibited spontaneous
ﬁbrillary collagen deposition from 10 weeks onward, as detected by
Collagen I staining (Fig. 2B–C). The extent of hepatic collagen expression
was further increased in an age-dependentmanner andwas substantial-
ly higher in transgenicmice compared toWT animals of the sameage. Of
note, the collagen staining pattern did not reﬂect true liver ﬁbrosis.
However, gene and protein expression of the ﬁbrosis marker alpha-
smooth-muscle-actin (α-SMA, predominantly expressed in activated
HSC) was signiﬁcantly higher in alb-myctg mice of all age cohorts incomparison to WT controls (Fig. 2D–E). Taking together increased
hepatic collagen accumulation and HSC activation in alb-myctg mice
indicates a predisposition to liver ﬁbrosis due to c-myc overexpression.
3.3. Overexpression of c-myc in hepatocytes is associated with alterations
in hepatic metabolism and induction of PDGF-B expression
It has been previously shown that c-myc can regulate cellular metab-
olism by transcriptional up-regulation of target genes involved in glucose
uptake and lactate production such as Lactate Dehydrogenase A (LDH-A)
[24,25]. Since a recent study suggested that accumulation of lactate in
liver has pro-ﬁbrotic properties [26], we evaluatedwhether the increased
collagen deposition in alb-myctg mice was related to c-myc-dependent
deregulation of the hepatic metabolism. To this end, we measured the
gene expression of key enzymes involved in glycolysis and lipogenesis
as illustrated in Fig. 3A. Unexpectedly, in alb-myctgmicewedidnot detect
aberrant expression of Pyruvate Kinase M1 (PKM1), which usually inac-
tivates the enzyme responsible for conversion of pyruvate to acetyl-
CoA. In addition, we observed down-regulation of LDH-A in c-myc trans-
genic mice suggesting that in our experimental setting c-myc expression
does not result in elevated lactate production (Fig. 3B). However, c-myc
overexpression inhibited lipogenesis-related genes as demonstrated by
the down-regulation of the Fatty Acid Binding Transporter 4 (FATP4)
and the Peroxisome Proliferator-activated Receptor gamma (PPARγ). Of
note, depletion of PPARγ is related to enhanced liver ﬁbrogenesis as
reported earlier [27].
We next investigated potential paracrine effects of c-myc over-
expressing hepatocytes in situ as this could explain improved activa-
tion of ﬁbrogenic cells in alb-myctg mice. Platelet-derived growth
factor B (PDGF-B) is one of the key players in development of hepatic
ﬁbrosis [15]. Interestingly, we detected cytoplasmic expression of
PDGF-B in hepatocytes from alb-myctg mice which was strong in
old animals and less frequent in young mice (Fig. 3C). In summary,
overexpression of c-myc in hepatocytes induces pro-ﬁbrotic signals
such as down-regulation of PPARγ and expression of PDGF-B.
3.4. Enhanced cell cycle progression andmyoﬁbroblast-transdifferentiation
of HSC from alb-myctg mice
We were next interested to deﬁne the cellular mechanism leading
to collagen deposition in alb-myctg livers and focussed on HSC as a
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Fig. 2. Age-dependent hepatic collagen deposition in alb-myctg mice. Tumor-free
alb-myctg mice and matching WT littermate controls at the age of 10 (n = 7 per
group) or 65 weeks (n = 7 per group) were analyzed for markers of proliferation,
apoptosis and liver ﬁbrosis. (A) Protein expression of PCNA and cleaved caspase-3
demonstrating elevated proliferation and apoptosis in aged alb-myctg liver. (B) Detection
of basal collagen deposition (collagen type I α1, stained in red) in liver of WT and
alb-myctg mice at the age of 10 weeks (10w, upper panel) and 65 weeks (65w, lower
panel) using immunoﬂuorescence microscopy. (C) Quantiﬁcation of collagen I stained
tissue area using image analysis software. (D) Quantiﬁcation of hepatic α-SMA mRNA
expression. (E) Determination of α-SMA protein expression in 65-week-old WT and
alb-myctg mice. *: p b 0.05; **: p b 0.01; ***: p b 0.001.
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alb-myctg mice and from WT controls of the same age (45 weeks old)
andmeasured c-myc andα-SMAmRNAexpression. Of note, HSC derived
from WT or alb-myctg mice showed the same basal c-myc expression
level (Supplementary Fig. 3A), which was expected since the c-myc
transgene was expressed speciﬁcally in hepatocytes. However, basal
α-SMA levels were signiﬁcantly up-regulated in freshly isolated HSCs
from alb-myctg animals (Fig. 4A) suggesting that the liver of alb-myctg
mice contains a population of pre-activated HSC.
To study this phenomenon inmore details we investigated cell cycle
progression, transdifferentiation and survival of HSC from WT and
alb-myctg mice in vitro over a time period of ten days (d1–d10). At the
beginning of the experiments both HSC populations were comparable
regarding density and purity as conﬁrmed bymicroscopy and visualiza-
tion of intracellular vitamin A droplets followingUV excitation (Supple-
mentary Fig. 3B).
HSC from alb-myctg mice revealed accelerated transactivation
compared to controls beginning already at day 3 after seeding.
After 7 days, the majority of HSC from transgenic animals had a
ﬁbroblast-like morphology and reached conﬂuence (Fig. 4B). Our
ﬁndings were conﬁrmed by gene expression analysis for α-SMA
and collagen I. In HSC from transgenic mice, overall α-SMA and
collagen expression signiﬁcantly exceeded WT levels at all investi-
gated time points (Fig. 4C–D). To monitor cell cycle progression
and transdifferentiation of HSC into myoﬁbroblasts, we performed
co-staining for Ki-67 andα-SMA. InWT HSC, around 5% of total HSC
were Ki-67 positive at day 4 after seeding (Fig. 5A). In contrast,
Ki-67 expression was detectable in more than 15% of HSC from
alb-myctg mice suggesting enhanced cell cycle activity of these
cells (Fig. 5A–B).
C-myc overexpression in alb-myctg mice was restricted to hepato-
cytes. Accordingly, HSC derived from alb-myctg mice showed an identi-
cal c-myc expression proﬁle compared to WT HSC revealing transient
c-myc induction limited to day 1 after plating (Fig. 5C). In our previous
work [17] we demonstrated that cell cycle progression, myoﬁbroblast-
transdifferentiation and survival of HSC depends on cyclin E1. In turn,
c-myc controls the activation of the cyclin E/-Cdk2 kinase complex
resulting in cell proliferation. In fact, transient c-myc induction in WT
HSC preceded the induction of cyclin E1 in these cells (Fig. 5D). We
thus compared cyclin E1 mRNA expression levels in HSC from WT and
alb-myctg mice throughout the transdifferentiation process. In line
with our previous ﬁnding, cyclin E1 expressionwas signiﬁcantly elevat-
ed in HSC from transgenic mice at days 3, 4 and 7 after plating (Fig. 5E).
Using immunoﬂuorescencemicroscopy, we could also demonstrate the
enhanced expression of cyclin E1 in nuclei of HSC from alb-myctg visible
already at day 3 after plating (Fig. 5F). From this data we conclude that
overexpression of c-myc in hepatocytes has the potential to prime
resident HSC for activation and proliferation while c-myc induction in
HSC is sharply restricted to an early phase of activation and does not
inﬂuence cyclin E1 expression.
One possible mechanism for HSC pre-activation through c-myc
expressing hepatocytes could be the c-myc-driven secretion of pro-
ﬁbrogenic mediators such as PDGF-B as already demonstrated in situ
(compare Fig. 3C). To further support this hypothesis, we stimulated pri-
mary WT HSC with conditioned medium derived either from cultured
alb-myctg hepatocytes (CM alb-myctg) or WT hepatocytes (CMWT) and
analyzed the kinetics of HSC transactivation in vitro. However, in this ex-
periment we did not detect morphological differences between CM
alb-myctg and CM WT treated HSC within the observation time of
10 days (Supplementary Fig. 4A). In line with this ﬁnding, induction of
α-SMA occurred with the same kinetics in both groups (Supplementary
Fig. 4B–C). Interestingly, treatment of WT HSC with conditioned
hepatocyte-derived medium per se accelerated the induction of α-SMA
and collagen I (Supplementary Fig. 4C–D). However, these effects were
c-myc independent and could also be achieved with CM WT to the
same extend. In summary, these experiments suggest that the crosstalk
10 weeks 55 weeks
WT WT
alb-myctg alb-myctg
PPARγ
0.0
0.5
1.0
1.5
***
PP
AR
γ/
GA
PD
H 
fo
ld
 
in
du
ct
io
n
LDH-A
0.0
0.5
1.0
1.5
***
LD
H 
A/
GA
PD
H 
fo
ld
 
in
du
ct
io
n
FATP4
0.0
0.5
1.0
1.5
2.0
*
FA
TP
4/
G
AP
DH
 
fo
ld
 
in
du
ct
io
n
PKM1
0.0
0.5
1.0
1.5
2.0
n.s.
Pk
m
/G
AP
DH
 
fo
ld
 
in
du
ct
io
n
B
C
A
WT
alb-myctg
Fig. 3. Overexpression of c-myc in hepatocytes is associatedwith alterations in hepatic metabolism and induces expression of PDGF-B. (A) Schematic overview of the analyzedmetabolic
pathways. Left: Glycolysis under hypoxic conditions resulting in lactate production. PKM1: Pyruvate kinase M1; LDH-A: Lactate Dehydrogenase A. Right: Glucose metabolism and
lipogenesis under normoxic conditions. TCA cycle: Tricarboxylic Acid cycle; FATP: Fatty Acid binding transporter; PPARγ: Peroxisome proliferator-activated receptor gamma. (B) Liver
samples fromWT and tumor-free alb-myctg mice at the age of 65 weeks (n = 7 per group) were analyzed for expression of genes involved in glycolysis (LDH-A, PKM1) and lipogenesis
(PPARγ, FATP4) by qPCR. *: p b 0.05; ***: p b 0.001; n.s.: not signiﬁcant. (C) Parafﬁn liver sections fromWT and tumor-free alb-myctg mice at the age of 10 and 55 weeks were stained
with an antibody for PDGF-B. Hepatocytes with cytoplasmic expression of PDGB-B are stained in brown (arrows).
1769Y.A. Nevzorova et al. / Biochimica et Biophysica Acta 1832 (2013) 1765–1775
da
y 
 
3
da
y 
 
7
alb-myctgWT
*
**
0 3 6 9
0
2
4
6
8
10
WT
alb-myctg
co
lla
ge
n/
G
AP
DH
 
m
RN
A
(fo
ld
 
in
du
ct
io
n)
*
days after isolation
Collagen I
0
1
2
3
SM
A/
G
AP
DH
 m
RN
A
(fo
ld 
in
du
ct
io
n)
*
SMA
alb-myctgWT
*
*
*
*
*
*
0 3 6 9
0
50
100
150
200
250
300
350
WT
alb-myctg
-
SM
A/
G
AP
DH
 m
RN
A
(fo
ld
 in
du
ct
io
n
)
-SMA
days after isolation
B
C
A
D
Fig. 4. Overexpression of c-myc in hepatocytes pre-activates HSC. Primary HSC were isolated from tumor-free alb-myctg mice and WT controls. For each experiment, HSC from a
minimum of 3 mice per group were pooled. A total number of 150,000 cells were seeded per 6-well plate and cultivated for up to 10 days (d1–d10). At time points indicated,
attached cells were harvested and analyzed. (A) Basal α-SMA mRNA expression in freshly isolated HSC from alb-myctg mice compared to matching WT controls. (B) Morphology
and cell density of HSC was determined by phase contrast microscopy at day 3 and day 7 after isolation. Original magniﬁcation: 100×. (C–D) Gene expression proﬁle of (C) α-SMA
and (D) collagen I in HSC derived from WT and alb-myctg mice.
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environment and cannot be mimicked in vitro.
3.5. Overexpression of c-myc in hepatocytes accelerates liver ﬁbrogenesis
during chronic CCl4 treatment
We next investigated the involvement of c-myc in experimental
murine liver ﬁbrosis. To this end, we subjectedWTmice to periodical
carbon tetrachloride (CCl4) injections for up to 4 weeks. In agree-
ment with our ﬁndings in human samples, c-myc mRNA and proteinexpression in murine liver was strongly induced after CCl4 treatment
and correlated with ﬁbrosis progression as determined by α-SMA
quantiﬁcation (Fig. 6A–B). Immunohistochemistry revealed that
following CCl4-treatment the c-myc protein accumulated in both
non-parenchymal cells and hepatocytes while c-myc could not be
detected in untreated control samples (Fig. 6C).
Based on our previous results, we hypothesized that c-myc
overexpression of hepatocytes in vivo could lead to an enhanced
propensity of mice to develop liver ﬁbrosis by facilitating HSC
activation. Therefore, we investigated the consequences of chronic
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Repeated injections of CCl4 for 2 weeks induced only minor colla-
gen expression in WT livers, whereas in livers from alb-myctg mice
bridging ﬁbers were already detectable in Sirius red stained tissue
sections (Fig. 7A–B). These ﬁndings were conﬁrmed by qPCR show-
ing approximately 3 times increased expression of hepatic α-SMA
in alb-myctg mice in comparison to WT controls (Fig. 7C). We also
performed expression analysis of pro-ﬁbrotic proteins conﬁrming
accelerated onset of α-SMA and collagen I expression in alb-myctg
(Fig. 7D). In addition, PCNA was also prematurely induced indicating
enhanced proliferation of hepatic cells in alb-myctg mice (Fig. 7D).
Consistently, immunohistological analysis of liver sections conﬁrmedincreased proliferation of hepatic cells in alb-myctg animals as evidenced
by Ki-67 staining (Fig. 7E).
A more detailed analysis demonstrated that in alb-myctg mice hepa-
tocytes aremore prone to proliferation compared toWT cells, while pro-
liferation of non-parenchymal cells was similar in WT- and alb-myctg
liver (Fig. 7F). In agreement with our previous observations, the gene
and protein expression of c-myc after 2 weeks of CCl4 administration
was signiﬁcantly stronger in the liver from transgenic mice compared
to WT animals (Fig. 7G–H). Our ﬁndings are summarized in Fig. 8 and
implicate that pre-activation of HSC by c-myc overexpressing hepato-
cytes primes the liver for accelerated ﬁbrosis induction at least in the
CCl4 model.
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Initiation and progression of liver ﬁbrosis is related to proliferation
of hepatic cells such as hepatocytes and HSC. As a consequence of
chronic liver injury and hepatocyte death, remnant hepatocytes leave
their quiescent state and re-enter the cell cycle in order to restore the
original liver mass and function. Hepatocyte death also stimulates the
proliferation and activation of HSC resulting in transdifferentiation
and matrix production. We recently demonstrated that the cell cycle
mediator cyclin E1 is essential for activation, proliferation and survival
of HSC during liver ﬁbrogenesis [17] thereby highlighting the yet
underestimated role of the cell cycle machinery for initiation of liver
ﬁbrosis. Cyclin E1 is under control of the proto-oncogene c-myc [28]. Al-
though it is well established that gene ampliﬁcation and overexpression
of c-myc is associated with development of hepatocellular carcinoma
[29–31], the time point of c-myc induction, but also its role for HCC
precursor stages such as ﬁbrosis is poorly characterized.
Here, we demonstrated for theﬁrst time that c-myc is over-expressed
in patients with advanced liver ﬁbrosis but also in experimental liver
ﬁbrosis in mice. Additionally, transgenic overexpression of c-myc exclu-
sively in hepatocytes triggered increased hepatic collagen deposition
andwas sufﬁcient to primewildtype-likeHSCwithnormal c-myc expres-
sion for accelerated activation. As a consequence, transgenic mice with
overexpression of c-myc in hepatocytes showed strongly accelerated
onset of liver ﬁbrosis following chronic injury.
Our results raised the question whether liver ﬁbrosis is rather trig-
gered by endogenous c-myc induction as a direct response to liver injury
or by constitutive c-myc expression due to acquired genetic instability
and gene ampliﬁcation. Of note, c-myc ampliﬁcation was described in
30%–80% of primary HCC in several studies [31–33]. We mimicked
c-myc ampliﬁcation by using transgenic alb-myctg mice, which is a
well-established animal model of hepatocarcinogenesis [30]. However,
continuous overexpression of c-myc exclusively in hepatocytes resulted
in only moderate HCC incidence of approximately 30%–60% within one
year [9,30]. From our owndata in alb-myctgmicewe conclude that gene
ampliﬁcation of c-myc in hepatocytes alone is not sufﬁcient to induce
true liver ﬁbrosis, but rather provides a pro-ﬁbrotic tissue environmentthrough basal moderate apoptosis, pre-activation of HSC and high basal
collagen expression eventually leading to stronger ﬁbrogenesis after
stimulation via a second hit. In contrast, our data from CCl4-treated
WT mice clearly indicated that chronic liver injury is associated with
induction of endogenous c-myc. Interestingly, c-myc expression levels
did not correlate with ﬁbrosis stage but were maximal at a medium
phase (F3 in patients; 2 weeks after CCl4 treatment in mice) of ﬁbrosis
progression further suggesting that regulated c-myc induction per se,
but not c-myc gene ampliﬁcation and constitutive expression, is a pre-
requisite for ﬁbrosis induction.
Another relevant matter in our study was the identiﬁcation of the
major target cell for c-myc mediated pro-ﬁbrotic processes. Our in
situ analysis in human ﬁbrotic livers revealed c-myc expression in
both hepatocytes and non-parenchymal cells such as HSC. However,
during HSC activation we detected only early and transient c-myc
induction which was identical in WT cells and pre-activated HSC
derived from alb-myctg mice. Moreover, we still detected strong cyclin
E1 expression, HSC proliferation and collagen production after c-myc
was turned off and remarkably, cyclin E1 expression was even higher
in HSC from alb-myctg mice in the absence of detectable c-myc gene
expression. We therefore conclude that c-myc is completely dispens-
able for cyclin E1 expression, cell cycle progression and transactivation
of HSC but is relevant as a trigger for early HSC activation.
Accordingly, c-myc expression in hepatocytes seems to be a major
trigger of liver ﬁbrosis. Our data clearly demonstrated that continuous
c-myc expression such as in alb-myctg mice resulted in moderate but
chronic hepatocyte apoptosis and pre-activated endogenous HSC for
accelerated proliferation and transdifferentiation induced by a second
stimulus. We therefore hypothesize that early acquirement of c-myc
ampliﬁcation would predispose patients with chronic hepatitis for
accelerated onset of severe liver ﬁbrosis and cirrhosis.
Mechanistically, our data point a crosstalk between c-myc expressing
hepatocytes andHSC through several independent signals. Recent studies
suggested that changes in the hepatic metabolism such as inhibition of
lipogenesis and lactate accumulation due to aerobic glycolysis may con-
tribute to HSC activation [26]. We initially hypothesized that alb-myctg
mice could be predisposed to liver ﬁbrosis due to enhanced pro-ﬁbrotic
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myc-expression under control of the Phosphoenolpyruvate carboxykinase
(PEPCK) promoter [25]. However our data clearly excluded this possibility.
Instead, c-myc overexpression largely preventedhepatic PPARγ expression.
Of note, PPARγ-deﬁcient mice are prone to enhanced liver ﬁbrosis after
injury [27].We thus conclude that c-mycmediated inhibition of lipogenesis
and down-regulation of PPARγmay contribute to pre-activation of HSC in
alb-myctg mice.
As a second potential mediator for the crosstalk between c-myc
expressing hepatocytes and HSC we identiﬁed PDGF-B, which is one of
the key ﬁbrogenic stimuli to HSC activation. We detected obvious cyto-
plasmic PDGF-B expression exclusively in hepatocytes of alb-myctgmice which increased with age. This was unexpected since hepato-
cytes are usually not the main source of PDGF in the liver. However,
previous studies have demonstrated that transgenic expression of
PDGF-B selectively in hepatocytes increases hepatic collagen deposition
in mice and predisposes to enhanced liver ﬁbrosis after CCl4 treatment
[34] reﬂecting several properties of alb-myctg mice. Therefore our data
strongly suggest that PDGF-B expression is induced in hepatocytes by
c-myc and allows for paracrine signaling on neighboringHSC contribut-
ing to their activation. However, we could not mimic these postulated
effects in vitro. Although our experiments using supernatants of hepato-
cyte cultures in vitro showed that paracrinemechanisms in hepatocytes
are able to drive HSC activation, we were not able to detect c-myc
Fig. 8. Proposed model explaining accelerated onset of liver ﬁbrosis in alb-myctg mice. It is suggested that c-myc in hepatocytes can either be up-regulated during chronic liver
injury or through genomic instability and c-myc gene ampliﬁcation. The latter one is mimicked in alb-myctg mice. Up-regulation of c-myc in hepatocytes is sufﬁcient to
pre-activate HSC in vivo and thus predisposes the liver for accelerated ﬁbrogenesis after a second hit. In addition, c-myc expression in hepatocytes also triggers moderate apoptosis
which may act synergistic with HSC pre-activation to trigger liver ﬁbrosis.
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However, we cannot exclude that stress signals during cell isolation in
the in vitro experiments overlapped with c-myc dependent paracrine
mechanisms. It has also been considered that c-myc/PDGF-B-mediated
liver ﬁbrogenesis may require long latency which is best illustrated by
the age-dependent increase of PDGF-B-positive hepatocytes in alb-
myctg mice. We therefore hypothesize that persistent physical interac-
tion of c-myc expressing hepatocytes and HSC in vivo is necessary to
explain HSC pre-activation and enhanced hepatic collagen deposition
in alb-myctg mice. In addition, this pro-ﬁbrotic tissue environment
may facilitate enhanced ﬁbrosis induced by a second hit such as CCl4.
Our conclusions and key ﬁndings are summarized in Fig. 8:
Up-regulation of c-myc in hepatocytes either due to genetic gene
ampliﬁcation or as a response to inﬂammatory liver injury results
in moderate hepatocyte apoptosis, enhanced hepatocyte prolifera-
tion and aberrant expression of PDGF-B. Close physical vicinity
of dying or PDGF-expressing hepatocytes with resident quiescent
HSC can synergistically lead to HSC pre-activation and moderatetransdifferentiation into myoﬁbroblasts with subsequent mild colla-
gen production. These primed HSC have a higher potential to pro-
duce extracellular matrix especially after a second pro-ﬁbrotic hit.
Therefore, overexpression of c-myc is a novel marker of liver ﬁbrosis
in man and mice which could be useful for improved diagnosis.
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